214 related articles for article (PubMed ID: 31125713)
1. Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption.
Al-Ali AAA; Nielsen RB; Steffansen B; Holm R; Nielsen CU
Int J Pharm; 2019 Jul; 566():410-433. PubMed ID: 31125713
[TBL] [Abstract][Full Text] [Related]
2. Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2).
Hanke U; May K; Rozehnal V; Nagel S; Siegmund W; Weitschies W
Eur J Pharm Biopharm; 2010 Oct; 76(2):260-8. PubMed ID: 20600890
[TBL] [Abstract][Full Text] [Related]
3. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
[TBL] [Abstract][Full Text] [Related]
4. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
5. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Weiss J; Sauer A; Divac N; Herzog M; Schwedhelm E; Böger RH; Haefeli WE; Benndorf RA
Biopharm Drug Dispos; 2010 Mar; 31(2-3):150-61. PubMed ID: 20222053
[TBL] [Abstract][Full Text] [Related]
6. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
7. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes.
Shono Y; Nishihara H; Matsuda Y; Furukawa S; Okada N; Fujita T; Yamamoto A
J Pharm Sci; 2004 Apr; 93(4):877-85. PubMed ID: 14999725
[TBL] [Abstract][Full Text] [Related]
8. Membrane transporter proteins: a challenge for CNS drug development.
Girardin F
Dialogues Clin Neurosci; 2006; 8(3):311-21. PubMed ID: 17117613
[TBL] [Abstract][Full Text] [Related]
9. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers.
Rege BD; Kao JP; Polli JE
Eur J Pharm Sci; 2002 Sep; 16(4-5):237-46. PubMed ID: 12208453
[TBL] [Abstract][Full Text] [Related]
10. Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.
Sasabe H; Shimokawa Y; Shibata M; Hashizume K; Hamasako Y; Ohzone Y; Kashiyama E; Umehara K
Antimicrob Agents Chemother; 2016 Jun; 60(6):3497-508. PubMed ID: 27021329
[TBL] [Abstract][Full Text] [Related]
11. Intestinal efflux transporters and drug absorption.
Murakami T; Takano M
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):923-39. PubMed ID: 18624680
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.
Sawangrat K; Yamashita S; Tanaka A; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
J Pharm Sci; 2019 Mar; 108(3):1315-1325. PubMed ID: 30389568
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.
Leslie EM; Deeley RG; Cole SP
Toxicol Appl Pharmacol; 2005 May; 204(3):216-37. PubMed ID: 15845415
[TBL] [Abstract][Full Text] [Related]
14. The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - An in vitro and in vivo comparison.
Weinheimer M; Fricker G; Burhenne J; Mylius P; Schubert R
Eur J Pharm Sci; 2017 Oct; 108():13-22. PubMed ID: 27590127
[TBL] [Abstract][Full Text] [Related]
15. Interaction of Food Additives with Intestinal Efflux Transporters.
Sjöstedt N; Deng F; Rauvala O; Tepponen T; Kidron H
Mol Pharm; 2017 Nov; 14(11):3824-3833. PubMed ID: 28921988
[TBL] [Abstract][Full Text] [Related]
16. The biological and clinical role of drug transporters at the intestinal barrier.
Oostendorp RL; Beijnen JH; Schellens JH
Cancer Treat Rev; 2009 Apr; 35(2):137-47. PubMed ID: 18986769
[TBL] [Abstract][Full Text] [Related]
17. Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions.
Zakeri-Milani P; Valizadeh H
Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):859-71. PubMed ID: 24708201
[TBL] [Abstract][Full Text] [Related]
18. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.
Neumanova Z; Cerveny L; Ceckova M; Staud F
AIDS; 2014 Jan; 28(1):9-17. PubMed ID: 24413260
[TBL] [Abstract][Full Text] [Related]
19. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins.
Bogman K; Erne-Brand F; Alsenz J; Drewe J
J Pharm Sci; 2003 Jun; 92(6):1250-61. PubMed ID: 12761814
[TBL] [Abstract][Full Text] [Related]
20. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Pedersen JM; Matsson P; Bergström CA; Norinder U; Hoogstraate J; Artursson P
J Med Chem; 2008 Jun; 51(11):3275-87. PubMed ID: 18457386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
